- c‑Cbl (Casitas B‑lineage lymphoma proto‑oncogene) is one of the most extensively studied single‑chain RING finger ubiquitin ligases, best known for its central role in controlling signalling through receptor tyrosine kinases (RTKs) such as EGFR, PDGFR, VEGFR and MET. As a single‑polypeptide E3 ligase, c‑Cbl contains both the catalytic RING domain and the substrate‑recognition modules within one protein, enabling rapid and direct regulation of signalling pathways that govern cell growth, differentiation, immune responses and oncogenesis.
- c‑Cbl is structurally organised into several functional domains. At the N‑terminus lies the TKB (tyrosine kinase‑binding) domain, composed of a four‑helix bundle, an EF hand and an SH2‑like region. This module allows c‑Cbl to bind phosphorylated tyrosine residues on activated RTKs or adaptor proteins. Adjacent to the TKB domain is the RING finger domain, a zinc‑binding module that interacts with ubiquitin‑charged E2 enzymes (E2~Ub). By positioning the E2~Ub complex close to the substrate, the RING domain enables direct transfer of ubiquitin without forming a covalent E3~Ub intermediate. The C‑terminal region contains proline‑rich motifs and a ubiquitin‑associated (UBA) domain, which facilitate interactions with signalling adaptors and ubiquitin chains.
- Functionally, c‑Cbl acts as a negative regulator of RTK signalling. Upon ligand stimulation, RTKs undergo autophosphorylation, creating docking sites for c‑Cbl. Once recruited, c‑Cbl ubiquitinates the receptor, typically assembling mono‑ubiquitin or K63‑linked chains. These modifications do not necessarily target the receptor for proteasomal degradation; instead, they serve as sorting signals for endocytosis and lysosomal trafficking, effectively attenuating signalling. Through this mechanism, c‑Cbl ensures that RTK activation is transient and tightly controlled, preventing excessive proliferative or inflammatory responses.
- Beyond RTKs, c‑Cbl regulates multiple signalling pathways. It modulates T‑cell receptor (TCR) signalling, influences integrin‑mediated adhesion, and participates in innate immune responses through interactions with adaptor proteins such as Grb2 and Crk. Its ability to bind phosphorylated substrates makes c‑Cbl a versatile regulator of tyrosine kinase‑dependent signalling networks. Mutations in c‑Cbl, particularly those affecting the RING domain or TKB domain, have been linked to myeloid malignancies, where defective ubiquitination leads to prolonged RTK signalling and uncontrolled cell proliferation.
- c‑Cbl also functions as a scaffold protein independent of its E3 ligase activity. Through its proline‑rich regions, it recruits SH3‑domain‑containing adaptors, shaping the assembly of signalling complexes. This dual role—both catalytic and structural—allows c‑Cbl to fine‑tune signalling outcomes in a context‑dependent manner.
- In summary, c‑Cbl is a key single‑chain RING finger ubiquitin ligase that maintains cellular homeostasis by regulating receptor tyrosine kinase signalling. Its ability to bind phosphorylated substrates, catalyse ubiquitination and orchestrate signalling complexes makes it essential for controlling cell growth, immune responses and differentiation. Dysregulation of c‑Cbl contributes to oncogenesis and immune disorders, highlighting its importance as both a biological regulator and a potential therapeutic target.
